title: [Rheumatology. Do coxibs pose a cardiovascular risk?].
abstract: There is ongoing controversy regarding the cardiovascular safety of coxibes. Inhibition of COX-2 may have a pro-coagulant effect though available data does not support a class effect in human use. In clinical practice, prudence with its prescription is recommended. In cases which require treatment beyond one week, the individual cardiovascular and gastrointestinal risks need to be assessed. If the risk is predominantly gastrointestinal, a COXIB is indicated. If the cardiovascular risk is major, then a classical NSAID with gastric protection may be more appropriate.
authors.affiliation: Service de rhumatologie, médecine physique et rehabilitation, Av. Pierre Decker 5, CHUV, 1011 Lausanne. aso@chuv.hospvd.ch
authors.forename: A
authors.initials: A
authors.lastname: So
authors.forename: P
authors.initials: P
authors.lastname: de Goumoëns
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D012307:Risk Factors
chemical_list: D016861:Cyclooxygenase Inhibitors